contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dignitana-ab-publishes-q2-2022-interim-report

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Dignitana

Strategic growth aligned with clear vision: Strong growth continues at 30 percentFinancial highlights Q2 2022Net sales amounted to 18,3 MSEK (14,0), an increase of 30 percent over the same period...

Strategic growth aligned with clear vision: Strong growth continues at 30 percentFinancial highlights Q2 2022<ul><li>Net sales amounted to 18,3 MSEK (14,0), an increase of 30 percent over the same period in 2021.</li><li>Operating result amounted to 0.1 MSEK (-9,4).</li><li>Net result after financial items amounted to -0,2 MSEK (-9,7).</li><li>Earnings per share were 0,00 SEK (-0,15).</li><li>Cash Balance amounted to 7,3 MSEK (36,3).</li><li>Average Daily Treatment Revenue (ADTR)* was 201 TSEK (163), an increase of 23 percent over the same period in 2021.</li></ul>Significant events during the period<ul><li></li></ul>The Annual Report for 2021 was published 28 April 2022.<ul><li></li></ul>The Annual General Meeting was held on 19 May 2022.<ul><li></li></ul>Catarina Mård Löwenadler became Chief Executive Officer of Dignitana on 19 May 2022.<ul><li></li></ul>The company appointed Ulf Jönsson as Chief Financial Officer beginning 1 July 2022.<ul><li></li></ul>Dignitana AB secured a line of credit in the amount of SEK 10 million from the company's largest shareholder, Agartha AB, to support the strategic growth of the company.Business highlights during the period<ul><li>The American Medical Association reaffirmed their policy supporting scalp cooling and reimbursement for the treatment.</li></ul>Key FiguresDIGNITANA GROUP Q2 Q2 Q1-Q2 2022 Q1-Q2 2021 Full Year 2021 2022 2021 Net sales, TSEK 18 14 34 148 27 203 &nbsp;57 073 284 038 Total revenues, TSEK 24 17 40 777 31 331 &nbsp;62 376 067 174 Net profit after -232 -9 -6 740 -17 324 -43 076 financial items, TSEK 660 Cash and bank balances, 7 312 36 7 312 36 333 &nbsp;14 501 TSEK 333 Earnings per share 0,00 -0,15 -0,10 -0,28 -0,66 before and after dilution, SEK Average Daily Treatment 201 163 190 146 147 Revenue*, TSEK* ADTR includes pay-per-treatment revenue from patients and facilities. Does not include lease revenue or disposable sales.All financial reports are available at www.dignitana.com/investor-relations/financial-reports/&nbsp;This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-08-2022 08:00 CET.